TELA Bio projects strong momentum ahead
TELA Bio outlined its financial trajectory for 2026, projecting at least 8 percent revenue growth as the company advances its commercial operations. The biomedical device manufacturer guided Q2 revenue to approximately 20 million dollars, signaling steady performance in the near term. Europe demonstrated particularly robust growth, expanding 41 percent, which underscores the international demand for the company's regenerative medicine solutions. The OviTex LTR product continues its U.S. market penetration, representing a key driver of the company's expansion strategy. These metrics reflect TELA Bio's ability to execute on its commercial objectives while navigating a competitive healthcare landscape.
MA
Wednesday, May 13, 2026 at 11:20 AM
0
0
1
2